Introduction

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 153-159

  Thomsen, Henrik S ^a,b   Marckmann, Peter ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gadolinium based contrast agents; Late adverse reactions; Nephrogenic systemic fibrosis

Indexed keywords

CHELATE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; EDITORIAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROGENIC SYTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; FIBROSIS; IMAGE ENHANCEMENT; METHODOLOGY; SKIN DISEASE;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; SKIN DISEASES;

EID: 43049106868     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.01.022     Document Type: Editorial

References (20)

1. Harpur E.S., Worah D., Halz P.-A., et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection. A new magnetic resonance imaging contrast agent. Invest Radiol 28 Suppl. 1 (1993) S28-S43
2. Varadarajan J.A., Crofts S.P., Carvalho J.F., et al. The synthesis and evaluation of macrocyclic gadolinium-DTPA-bis(amide) complexes as magnetic resonance imaging contrast agents. Invest Radiol 24 Suppl. 2 (1994) S18-S20
3. Watson A.D., Rocklage S.M., and Carvlin M.J. Contrast agents. In: Stark D.D., and Bradley Jr. W.G. (Eds). Magnetic resonance imaging. 2nd ed. (1992), Mosby Year book, St. Louis 372-437
4. Cacheris W.P., Quay S.C., and Rocklage S.M. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imag 8 (1990) 467-481
5. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
6. Marzella L., Blank M., Gelperin K., and Johann-Liang R. Safety risks with gadolinium-based contrast agents (letter to the editor). J Magn Res Imag 26 (2007) 816
7. Idee J.-M., Port M., Raynal I., Schaefer M., Greneur S.L., and Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fund Clinl Pharmacol 20 (2006) 563-576
8. Thomsen H.S., and Morcos S.K. Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration?. Eur Radiol 15 (2005) 749-754
9. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
10. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
11. Levey A.S., Greene T., Kusek J., and Beck G.A. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 155A
12. Levey A.S., Coresh J., Greene T., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007) 766-772
13. Bostom A.G., Kronenberg F., and Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13 (2002) 2140-2144
14. Stevens L.A., Coresh J., Greene T., and Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
15. Band R.A., Gaieski D.F., Mills A.M., et al. Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast induced nephropathy. Am J Emerg Med 25 (2007) 268-272
16. Eken C., and Kilicaslan I. Differences between various glomerular filtration rate calculation methods in predicting patients at risk for contrast-induced nephropathy. Am J Emerg Med 25 (2007) 487 (Correspondence)
17. White G.W., Gibby W.A., and Tweedle M.F. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 (2006) 272-278
18. Abraham J.L., Thakral C., Skov L., et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Brit J Dermatol 158 (2008) 273-280
19. Thomsen H.S., Marckmann P., and Logager V.B. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. Acta Radiol 48 (2007) 593-596
20. Thomsen H.S., Marckmann P., and Logager V.B. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7 (2007) 130-137